Volume 48, Number 2, 370-378, DOI: 10.1007/s00125-004-1628-8

Published in partnership with the

Logo

European Association for the Study of Diabetes

Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study

M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, C. D. A. Stehouwer and EURODIAB Prospective Complications Study Group

View Related Documents

Abstract

Aims/hypothesis  

The pathogenesis of vascular complications in type 1 diabetes is poorly understood, but may involve chronic, low-grade inflammation. We investigated the association of markers of inflammation with vascular complications in type 1 diabetes.

Methods  

A cross-sectional nested case-control study of the follow-up data of the EURODIAB Prospective Complications Study. This study included 543 individuals (278 men) with type 1 diabetes diagnosed at <36 years of age. Cases (n=348) had complications of diabetes, controls (n=195) had no complications.

Results  

C-reactive protein, interleukin-6 and tumour necrosis factor-agr levels, which were combined in an inflammatory marker Z-score, were associated with albuminuria, retinopathy and cardiovascular disease. Calculated means (95% confidence intervals) of the marker Z-score were –0.15 (–0.22 to –0.07), 0.10 (–0.05 to 0.25), and 0.28 (0.15 to 0.41), p for trend <0.0001, in individuals with normo-, micro- and macroalbuminuria; –0.23 (–0.33 to –0.13), 0.14 (0.02 to 0.25) and 0.20 (0.07 to 0.32), p for trend <0.0001, in individuals with no, non-proliferative and proliferative retinopathy; and –0.28 (–0.39 to –0.18) and 0.06 (–0.08 to 0.20), p<0.001, in individuals without and with cardiovascular disease. Per 1 SD increase of the inflammatory marker Z-score, GFR decreased by –4.6 (–6.6 to –2.6) ml per min per 1.73 m2 (p<0.001).

Conclusions/interpretation  

We have shown that markers of inflammation are strongly and independently associated with microvascular complications and cardiovascular disease in type 1 diabetes. These data suggest that strategies to decrease inflammatory activity may help to prevent the development of vascular complications in type 1 diabetes.

Keywords  Advanced glycation endproducts - Cardiovascular disease - C-reactive protein - Diabetes - Interleukin-6 - Microvascular complications - Tumour necrosis factor-agr

Fulltext Preview

Image of the first page of the fulltext document